Skip to main content
Premium Trial:

Request an Annual Quote

Hans Peter Fatscher, Robert Langer

Premium
Qiagen has promoted Hans Peter Fatscher to vice president of life sciences sales, the company said last week. Fatscher has worked at Qiagen since 2001 in sales management and other sales areas, including director of global customer satisfaction.
 
In his new position at Qiagen, Fatscher will be responsible for North American life science sales and will work to standardize the company’s life sciences commercial processes in North America.
 
Fatscher spent about eight years in sales at a company owned by Boehringer Ingelheim, and ran his own consulting firm for three years before joining Qiagen.
 

 
Robert Langer has been named chairman of Boston Life Sciences’ science and technology committee, the company said this week.
 
The committee will assist Boston Life Sciences with drug discovery and development strategies, identify processes for evaluating and acquiring technology, and review the company’s research and development programs.
 
Langer is currently an institute professor at the Massachusetts Institute of Technology, where he researches, among other things, drug delivery technologies. Recently, Alnylam Pharmaceuticals in-licensed siRNA delivery technology developed in his lab (see RNAi News, 12/7/2006).

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.